Scaling the Andean Shilajit: A Novel Neuroprotective Agent for Alzheimer's Disease.

Autor: Andrade V; Laboratory of Neuroscience and Functional Medicine, International Center for Biomedicine, Faculty of Sciences, University of Chile, Santiago 7800003, Chile.; Division of Neurogenetics and Molecular Psychiatry, Department of Psychiatry and Psychotherapy, Medical Faculty, University of Cologne, 50923 Köln, Germany.; Department of Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital Bonn, 53127 Bonn, Germany., Wong-Guerra M; Laboratory of Neuroscience and Functional Medicine, International Center for Biomedicine, Faculty of Sciences, University of Chile, Santiago 7800003, Chile.; Laboratory of Toxicology and Metabolism, Faculty of Chemistry and Biology, University of Santiago of Chile, Santiago 9170022, Chile., Cortés N; Laboratory of Neuroscience and Functional Medicine, International Center for Biomedicine, Faculty of Sciences, University of Chile, Santiago 7800003, Chile., Pastor G; Laboratory of Neuroscience and Functional Medicine, International Center for Biomedicine, Faculty of Sciences, University of Chile, Santiago 7800003, Chile.; Laboratory of Toxicology and Metabolism, Faculty of Chemistry and Biology, University of Santiago of Chile, Santiago 9170022, Chile., González A; Laboratory of Neuroscience and Functional Medicine, International Center for Biomedicine, Faculty of Sciences, University of Chile, Santiago 7800003, Chile., Calfío C; Laboratory of Neuroscience and Functional Medicine, International Center for Biomedicine, Faculty of Sciences, University of Chile, Santiago 7800003, Chile., Guzmán-Martínez L; Laboratory of Neuroscience and Functional Medicine, International Center for Biomedicine, Faculty of Sciences, University of Chile, Santiago 7800003, Chile., Navarrete LP; Laboratory of Neuroscience and Functional Medicine, International Center for Biomedicine, Faculty of Sciences, University of Chile, Santiago 7800003, Chile.; Biochemistry School, Faculty of Health Sciences, Andres Bello University, Santiago 8370035, Chile., Ramos-Escobar N; Laboratory of Neuroscience and Functional Medicine, International Center for Biomedicine, Faculty of Sciences, University of Chile, Santiago 7800003, Chile., Morales I; Laboratory of Neuroscience and Functional Medicine, International Center for Biomedicine, Faculty of Sciences, University of Chile, Santiago 7800003, Chile., Santander R; Laboratory of Kinetics and Photochemistry, Faculty of Chemistry and Biology, University of Santiago of Chile, Santiago 9170022, Chile., Andrades-Lagos J; Facultad de Medicina y Ciencia, Universidad San Sebastián, Santiago 7510157, Chile.; Drug Development Laboratory, Faculty of Chemical and Pharmaceutical Sciences, University of Chile, Santiago 8380492, Chile., Bacho M; Organic and Organometallic Synthesis Laboratory, Faculty of Chemistry, Andrés Bello University, Santiago 8370186, Chile.; Laboratory of Natural Resources, Faculty of Sciences, University of Chile, Santiago 7750000, Chile., Rojo LE; Laboratory of Toxicology and Metabolism, Faculty of Chemistry and Biology, University of Santiago of Chile, Santiago 9170022, Chile., Maccioni RB; Laboratory of Neuroscience and Functional Medicine, International Center for Biomedicine, Faculty of Sciences, University of Chile, Santiago 7800003, Chile.
Jazyk: angličtina
Zdroj: Pharmaceuticals (Basel, Switzerland) [Pharmaceuticals (Basel)] 2023 Jul 04; Vol. 16 (7). Date of Electronic Publication: 2023 Jul 04.
DOI: 10.3390/ph16070960
Abstrakt: Alzheimer's disease (AD) is a multifactorial neurodegenerative disorder without a cure, despite the enormous number of investigations and therapeutic approaches. AD is a consequence of microglial responses to "damage signals", such as aggregated tau oligomers, which trigger a neuro-inflammatory reaction, promoting the misfolding of cytoskeleton structure. Since AD is the most prevalent cause of dementia in the elderly (>60 years old), new treatments are essential to improve the well-being of affected subjects. The pharmaceutical industry has not developed new drugs with efficacy for controlling AD. In this context, major attention has been given to nutraceuticals and novel bioactive compounds, such as molecules from the Andean Shilajit (AnSh), obtained from the Andes of Chile. Primary cultures of rat hippocampal neurons and mouse neuroblastoma cells were evaluated to examine the functional and neuroprotective role of different AnSh fractions. Our findings show that AnSh fractions increase the number and length of neuronal processes at a differential dose. All fractions were viable in neurons. The AnSh fractions inhibit tau self-aggregation after 10 days of treatment. Finally, we identified two candidate molecules in M3 fractions assayed by UPLC/MS. Our research points to a novel AnSh-derived fraction that is helpful in AD. Intensive work toward elucidation of the molecular mechanisms is being carried out. AnSh is an alternative for AD treatment or as a coadjuvant for an effective treatment.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje